Cheap SS­RI drug proves suc­cess­ful in re­duc­ing Covid-re­lat­ed hos­pi­tal­iza­tion times in large tri­al

An­oth­er weapon against Covid-19 could be made more promi­nent as re­sults from a large, place­bo-con­trolled tri­al pub­lished in the Lancet on Wednes­day evening pro­vide com­pelling ev­i­dence that the cheap SS­RI flu­vox­am­ine may re­duce Covid-re­lat­ed hos­pi­tal­iza­tion times.

Of the 741 par­tic­i­pants who re­ceived flu­vox­am­ine in the tri­al in Brazil, 79, or 10.6%, re­quired an ex­tend­ed stay for more than six hours in an emer­gency set­ting or hos­pi­tal­iza­tion, com­pared to 119 out of the 756 (15.7%) par­tic­i­pants who re­ceived place­bo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER